General Information of Drug (ID: DMJDYNQ)

Drug Name
E-2007
Synonyms Perampanel; E 2007; Perampanel (USAN); 2-(2-oxo-1-phenyl-5-pyridin-2-yl-pyridin-3-yl)benzonitrile; 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one
Indication
Disease Entry ICD 11 Status REF
Diabetic neuropathy 8C0Z Approved [1]
Parkinson disease 8A00.0 Discontinued in Phase 3 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 349.4
Logarithm of the Partition Coefficient (xlogp) 3.4
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption
The drug is rapidly and completely absorbed following oral administration []
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.1 mL/min/kg [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 105 hours [3]
Metabolism
The drug is metabolized via the CYP3A4 and/or CYP3A5 primary oxidation and by sequential glucuronidation []
Unbound Fraction
The unbound fraction of drug in plasma is 0.05% [3]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.36 L/kg [3]
Chemical Identifiers
Formula
C23H15N3O
IUPAC Name
2-(2-oxo-1-phenyl-5-pyridin-2-ylpyridin-3-yl)benzonitrile
Canonical SMILES
C1=CC=C(C=C1)N2C=C(C=C(C2=O)C3=CC=CC=C3C#N)C4=CC=CC=N4
InChI
InChI=1S/C23H15N3O/c24-15-17-8-4-5-11-20(17)21-14-18(22-12-6-7-13-25-22)16-26(23(21)27)19-9-2-1-3-10-19/h1-14,16H
InChIKey
PRMWGUBFXWROHD-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
9924495
ChEBI ID
CHEBI:71013
CAS Number
380917-97-5
DrugBank ID
DB08883
TTD ID
D0U3ED
INTEDE ID
DR1256
ACDINA ID
D00519
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glutamate receptor AMPA (GRIA) TTAN6JD NOUNIPROTAC Modulator [4]
Glutamate receptor AMPA 1 (GRIA1) TTVPQTF GRIA1_HUMAN Inhibitor [5]
Glutamate receptor AMPA 2 (GRIA2) TT9HLZ0 GRIA2_HUMAN Inhibitor [5]
Glutamate receptor AMPA 3 (GRIA3) TT82EZV GRIA3_HUMAN Inhibitor [5]
Glutamate receptor AMPA 4 (GRIA4) TTPJR0G GRIA4_HUMAN Inhibitor [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME
DE4LYSA CP3A4_HUMAN Substrate [6]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [7]
Cytochrome P450 3A5 (CYP3A5)
Main DME
DEIBDNY CP3A5_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Diabetic neuropathy
ICD Disease Classification 8C0Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Glutamate receptor AMPA 1 (GRIA1) DTT GRIA1 1.46E-06 -0.63 -0.78
Glutamate receptor AMPA (GRIA) DTT NO-GeName 1.79E-04 -0.69 -0.58
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 7.36E-01 1.62E-02 1.08E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 9.96E-01 -3.17E-03 -1.84E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from E-2007 (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of E-2007 caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [9]
Pexidartinib DMS2J0Z Moderate Increased metabolism of E-2007 caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [9]
Levomilnacipran DMV26S8 Moderate Antagonize the effect of E-2007 when combined with Levomilnacipran. Chronic pain [MG30] [10]
Vortioxetine DM6F1PU Moderate Antagonize the effect of E-2007 when combined with Vortioxetine. Depression [6A70-6A7Z] [10]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of E-2007 and Esketamine. Depression [6A70-6A7Z] [11]
Oestradiol valerate and dienogest DMZK0FQ Moderate Increased metabolism of E-2007 caused by Oestradiol valerate and dienogest mediated induction of CYP450 enzyme. Endometriosis [GA10] [9]
PF-06463922 DMKM7EW Moderate Increased metabolism of E-2007 caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [9]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of E-2007 and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [12]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of E-2007 and Lasmiditan. Migraine [8A80] [13]
Elagolix DMB2C0E Moderate Increased metabolism of E-2007 caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [9]
⏷ Show the Full List of 10 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Perampanel 10 mg tablet 10 mg Oral Tablet Oral
Perampanel 12 mg tablet 12 mg Oral Tablet Oral
Perampanel 2 mg tablet 2 mg Oral Tablet Oral
Perampanel 8 mg tablet 8 mg Oral Tablet Oral
Perampanel 4 mg tablet 4 mg Oral Tablet Oral
Perampanel 6 mg tablet 6 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7050).
2 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
5 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
6 The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015 Jan;56(1):12-27.
7 Perampanel (Fycompa): a review of clinical efficacy and safety in epilepsy. P T. 2016 Nov;41(11):683-698.
8 FDA label of Perampanel. The 2020 official website of the U.S. Food and Drug Administration.
9 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
10 Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
11 Cerner Multum, Inc. "Australian Product Information.".
12 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
13 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.